ELAN
Price
$23.47
Change
+$0.23 (+0.99%)
Updated
Jan 9 closing price
Capitalization
11.66B
45 days until earnings call
Intraday BUY SELL Signals
EVO
Price
$3.66
Change
-$0.02 (-0.54%)
Updated
Jan 9 closing price
Capitalization
1.31B
80 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

ELAN vs EVO

Header iconELAN vs EVO Comparison
Open Charts ELAN vs EVOBanner chart's image
Elanco Animal Health
Price$23.47
Change+$0.23 (+0.99%)
Volume$2.86M
Capitalization11.66B
Evotec SE
Price$3.66
Change-$0.02 (-0.54%)
Volume$43.5K
Capitalization1.31B
ELAN vs EVO Comparison Chart in %
ELAN
Daily Signal:
Gain/Loss:
EVO
Daily Signal:
Gain/Loss:
View a ticker or compare two or three
VS
ELAN vs. EVO commentary
Jan 12, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ELAN is a Hold and EVO is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Jan 12, 2026
Stock price -- (ELAN: $23.47 vs. EVO: $3.66)
Brand notoriety: ELAN: Notable vs. EVO: Not notable
Both companies represent the Pharmaceuticals: Generic industry
Current volume relative to the 65-day Moving Average: ELAN: 53% vs. EVO: 26%
Market capitalization -- ELAN: $11.66B vs. EVO: $1.31B
ELAN [@Pharmaceuticals: Generic] is valued at $11.66B. EVO’s [@Pharmaceuticals: Generic] market capitalization is $1.31B. The market cap for tickers in the [@Pharmaceuticals: Generic] industry ranges from $3.76T to $0. The average market capitalization across the [@Pharmaceuticals: Generic] industry is $22.12B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ELAN’s FA Score shows that 1 FA rating(s) are green whileEVO’s FA Score has 1 green FA rating(s).

  • ELAN’s FA Score: 1 green, 4 red.
  • EVO’s FA Score: 1 green, 4 red.
According to our system of comparison, ELAN is a better buy in the long-term than EVO.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ELAN’s TA Score shows that 6 TA indicator(s) are bullish while EVO’s TA Score has 5 bullish TA indicator(s).

  • ELAN’s TA Score: 6 bullish, 4 bearish.
  • EVO’s TA Score: 5 bullish, 4 bearish.
According to our system of comparison, ELAN is a better buy in the short-term than EVO.

Price Growth

ELAN (@Pharmaceuticals: Generic) experienced а +4.22% price change this week, while EVO (@Pharmaceuticals: Generic) price change was +15.09% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was +1.96%. For the same industry, the average monthly price growth was +8.75%, and the average quarterly price growth was +20.89%.

Reported Earning Dates

ELAN is expected to report earnings on Feb 25, 2026.

EVO is expected to report earnings on Apr 01, 2026.

Industries' Descriptions

@Pharmaceuticals: Generic (+1.96% weekly)

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ELAN($11.7B) has a higher market cap than EVO($1.31B). EVO YTD gains are higher at: 18.831 vs. ELAN (3.712). ELAN has higher annual earnings (EBITDA): 840M vs. EVO (-116.99M). ELAN has more cash in the bank: 505M vs. EVO (243M). EVO has less debt than ELAN: EVO (96.9M) vs ELAN (4.02B). ELAN has higher revenues than EVO: ELAN (4.59B) vs EVO (756M).
ELANEVOELAN / EVO
Capitalization11.7B1.31B890%
EBITDA840M-116.99M-718%
Gain YTD3.71218.83120%
P/E Ratio335.29N/A-
Revenue4.59B756M607%
Total Cash505M243M208%
Total Debt4.02B96.9M4,153%
FUNDAMENTALS RATINGS
ELAN vs EVO: Fundamental Ratings
ELAN
EVO
OUTLOOK RATING
1..100
4346
VALUATION
overvalued / fair valued / undervalued
1..100
95
Overvalued
91
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9095
PRICE GROWTH RATING
1..100
3852
P/E GROWTH RATING
1..100
22
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

EVO's Valuation (91) in the null industry is in the same range as ELAN (95) in the Agricultural Commodities Or Milling industry. This means that EVO’s stock grew similarly to ELAN’s over the last 12 months.

EVO's Profit vs Risk Rating (100) in the null industry is in the same range as ELAN (100) in the Agricultural Commodities Or Milling industry. This means that EVO’s stock grew similarly to ELAN’s over the last 12 months.

ELAN's SMR Rating (90) in the Agricultural Commodities Or Milling industry is in the same range as EVO (95) in the null industry. This means that ELAN’s stock grew similarly to EVO’s over the last 12 months.

ELAN's Price Growth Rating (38) in the Agricultural Commodities Or Milling industry is in the same range as EVO (52) in the null industry. This means that ELAN’s stock grew similarly to EVO’s over the last 12 months.

ELAN's P/E Growth Rating (2) in the Agricultural Commodities Or Milling industry is in the same range as EVO (2) in the null industry. This means that ELAN’s stock grew similarly to EVO’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ELANEVO
RSI
ODDS (%)
Bearish Trend 3 days ago
67%
Bearish Trend 3 days ago
76%
Stochastic
ODDS (%)
Bearish Trend 3 days ago
67%
Bearish Trend 3 days ago
83%
Momentum
ODDS (%)
Bullish Trend 3 days ago
62%
Bullish Trend 3 days ago
69%
MACD
ODDS (%)
Bullish Trend 3 days ago
67%
N/A
TrendWeek
ODDS (%)
Bullish Trend 3 days ago
69%
Bullish Trend 3 days ago
68%
TrendMonth
ODDS (%)
Bullish Trend 3 days ago
70%
Bullish Trend 3 days ago
61%
Advances
ODDS (%)
Bullish Trend 3 days ago
65%
Bullish Trend 4 days ago
67%
Declines
ODDS (%)
Bearish Trend 10 days ago
72%
Bearish Trend 12 days ago
79%
BollingerBands
ODDS (%)
Bearish Trend 3 days ago
58%
Bearish Trend 3 days ago
75%
Aroon
ODDS (%)
Bullish Trend 3 days ago
77%
Bullish Trend 3 days ago
55%
View a ticker or compare two or three
Interact to see
Advertisement
ELAN
Daily Signal:
Gain/Loss:
EVO
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
PAWZ55.750.48
+0.87%
ProShares Pet Care ETF
TSI4.900.04
+0.82%
TCW Strategic Income Fund
RWO45.970.03
+0.07%
SPDR® Dow Jones® Global Real Estate ETF
GIND25.91-0.33
-1.24%
Goldman Sachs India Equity ETF
UNHG18.12-0.29
-1.58%
Leverage Shares 2X Long UNH Daily ETF

ELAN and

Correlation & Price change

A.I.dvisor indicates that over the last year, ELAN has been loosely correlated with VTRS. These tickers have moved in lockstep 48% of the time. This A.I.-generated data suggests there is some statistical probability that if ELAN jumps, then VTRS could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ELAN
1D Price
Change %
ELAN100%
+0.99%
VTRS - ELAN
48%
Loosely correlated
+1.27%
ZTS - ELAN
48%
Loosely correlated
+0.25%
PAHC - ELAN
40%
Loosely correlated
-0.70%
SNDL - ELAN
39%
Loosely correlated
+1.22%
AMPH - ELAN
36%
Loosely correlated
N/A
More

EVO and

Correlation & Price change

A.I.dvisor indicates that over the last year, EVO has been loosely correlated with SNDL. These tickers have moved in lockstep 42% of the time. This A.I.-generated data suggests there is some statistical probability that if EVO jumps, then SNDL could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To EVO
1D Price
Change %
EVO100%
-0.54%
SNDL - EVO
42%
Loosely correlated
+1.22%
PRGO - EVO
28%
Poorly correlated
+2.59%
ACET - EVO
26%
Poorly correlated
-0.74%
ELAN - EVO
24%
Poorly correlated
+0.99%
TKNO - EVO
24%
Poorly correlated
+4.49%
More